At-a-Glance | |
| Issue No. 17 | July 26, 2018 |
AIDSinfo Releases Updated Edition of HIV/AIDS Glossary
AIDSinfo is pleased to announce the release of the 9th edition of the AIDSinfo Glossary of HIV/AIDS-Related Terms! The glossary, which includes definitions for more than 700 HIV/AIDS-related terms in English and Spanish, provides people living with HIV, their families and friends, health care professionals, and students a guide to understanding HIV. Images that accompany many terms help to explain complex HIV/AIDS-related concepts. The updated glossary includes several new terms and images that reflect advances in HIV research.
The AIDSinfo HIV/AIDS glossary is available online, in print, and as an app. Visit AIDSinfo to download the free glossary app for your iOS or Android device or to order a printed copy of the English or Spanish glossary.
AIDSinfo welcomes your feedback on the glossary. Please email your questions or comments to ContactUs@aidsinfo.nih.gov.
The AIDSinfo HIV/AIDS glossary is available online, in print, and as an app. Visit AIDSinfo to download the free glossary app for your iOS or Android device or to order a printed copy of the English or Spanish glossary.
AIDSinfo welcomes your feedback on the glossary. Please email your questions or comments to ContactUs@aidsinfo.nih.gov.
AIDSinfo Releases Fact Sheet on Symtuza, a New Combination Drug to Treat Certain Adults with HIV
On July 17, 2018, the Food and Drug Administration (FDA) approved Symtuza, a new combination antiretroviral drug to treat HIV infection in adults:
- who have never taken HIV medicines before, or
- who have a viral load less than 50 copies per mL, have been on a stable treatment regimen for at least 6 months, and have no known substitutions associated with resistance to darunavir or tenofovir.
The 4-drug (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) fixed-dose combination tablet is a complete regimen for the treatment of HIV infection and should not be used with other HIV medicines.
For more information on Symtuza, please see the AIDSinfo Symtuza fact sheet [en español].
Do you want to learn more about HIV medicines? Check out the AIDSinfo FDA-Approved HIV Medicines fact sheet.
For more information on Symtuza, please see the AIDSinfo Symtuza fact sheet [en español].
Do you want to learn more about HIV medicines? Check out the AIDSinfo FDA-Approved HIV Medicines fact sheet.
Updates to the Influenza Section of the Pediatric Opportunistic Infections Guidelines
The Influenza section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children has been updated. Major revisions include additional graded recommendations on influenza vaccination, chemoprophylaxis, and antiviral treatment for children with HIV. The section has been updated to reflect the new recommendation rating system and additional references were added. For more information, see What's New in the Guidelines.
Recent HIV News from NIAID
No hay comentarios:
Publicar un comentario